5,000,000 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Bought by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,000,000 shares of the company's stock, valued at approximately $8,650,000. Adage Capital Partners GP L.L.C. owned 2.44% of Taysha Gene Therapies as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $2,528,000. Avoro Capital Advisors LLC grew its holdings in shares of Taysha Gene Therapies by 7.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock worth $34,600,000 after acquiring an additional 1,349,999 shares during the last quarter. B Group Inc. acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $1,670,000. Renaissance Technologies LLC purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at $1,520,000. Finally, Geode Capital Management LLC boosted its position in shares of Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock valued at $7,163,000 after purchasing an additional 682,273 shares during the period. Institutional investors own 77.70% of the company's stock.

Wall Street Analyst Weigh In

TSHA has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. JMP Securities reissued a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, Chardan Capital restated a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies has an average rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Stock Up 7.1 %

TSHA stock traded up $0.17 during trading hours on Friday, reaching $2.58. 5,758,382 shares of the stock were exchanged, compared to its average volume of 2,749,308. The firm's 50-day moving average is $1.59 and its 200-day moving average is $1.80. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $4.32. The company has a market cap of $529.04 million, a price-to-earnings ratio of 4.10 and a beta of 0.90. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.